On April 1, 2024, Astrazeneca announced the FDA approval of its "first-in-class" oral smal
READ MORE 2024-04-24News List
Astrazeneca's "first-in-class" oral small molecule is approved by the FDA
Nature Biotechnology | Antibody Drug Conjugators (ADCs) : ushering in a new era of precision cancer therapy
Recent studies have shown that by improving the linking technology and developing novel drug carrier
READ MORE 2024-03-15
The oral version of Semaglutide was approved for domestic market, and clinical results showed that it can effectively reduce blood sugar and lose weight
On January 26, 2024, the official website of the State Food and Drug Administration showed that the
READ MORE 2024-02-06
Semaglutide has a real rival! Lilly's strongest weight-loss drug, tilpotide is approved by the FDA
The FDA approved Tizepatide, developed by Eli Lilly and Company, as a weight loss drug (trade name Z
READ MORE 2023-11-30
It can restore 80% hair growth, and Pfizer's new drug for alopecia areata was approved for sale in China, which can treat adolescent alopecia areata
On October 19, 2023, the official website of China's State Drug Administration showed that it ap
READ MORE 2023-11-01
155 million dollars! Hengrui Medicine has another innovative drug to go to sea
Hengray Pharmaceutical announced that it has entered into an agreement with Dr. Reddy's Laborato
READ MORE 2023-10-09
Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy
On September 9, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") announced
READ MORE 2023-09-13
Researchers at Zhejiang University School of Medicine have revealed that the concept of targeting DDK can improve the efficacy of immunotherapy for liver cancer
Hepatocellular carcinoma is a common and highly aggressive tumor that has been recognized as the sev
READ MORE 2023-08-29
On July 14, Bojian's listing application for tofersen injection was accepted.
On April 25, 2023, the FDA accelerated approval of the antisense oligonucleotide therapy tofersen (Q
READ MORE 2023-07-30
The annual bleeding rate of patients was reduced by 71%, and Pfizer's marketing application for hemophilia gene therapy was accepted by the FDA
Pfizer, Inc. (NYSE: PFE) today announced that the FDA has accepted a biologics license application (
READ MORE 2023-07-03